| Cellular drug action profile paradigm applied to XK469. | |
| | |
MedLine Citation:
|
PMID: 12416029 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The cellular paradigm presented here defines the cellular action profile of new anticancer agents that complements our discovery and development paradigm. The main elements of this profile include a concentration clonogenicity response relationship on proliferating and plateau phase cells, flow cytometry studies assessing progression delay and apoptosis, macromolecular synthesis inhibition, and DNA damage assessment by the comet assay; other specific assessments then derive from these findings such as topoisomerase assays. XK469 is a new anticancer agent derived from the herbicide Assure that is the inactive parent compound of a family of quinoxaline analogs found to have anticancer activity in vivo. We have applied the described cellular action profile paradigm to XK469 to define a novel action at the cellular level. XK469 is a G2M phase-specific, antiproliferative agent whose activity is related to the 7-position of the chlorine ion in the benzene ring and expressed through a unique cellular action profile resulting in the irreversible increase in cyclin B1 (possibly by specific inhibition of its ubiquitination) and leading, in the absence of apoptosis, to the final mitotic arrest of HCT-116 cells in prophase with subsequent loss of clonogenicity. |
| | |
Authors:
|
Balanehru Subramanian; Alexander Nakeff; Joseph Media; Mark Wentland; Frederick Valeriote |
Related Documents
:
|
21364649 - Pro-apoptotic bax is the major and bak an auxiliary effector in cytokine deprivation-in... 21139139 - A kinase-independent role for unoccupied insulin and igf-1 receptors in the control of ... 9380719 - Telomere lengthening and telomerase activation during human b cell differentiation. 21138749 - Mitochondrial targeting by use of lipid nanocapsules loaded with sv30, an analogue of t... 22772799 - Bacterial tir-containing proteins and host innate immune system evasion. 21341029 - Detection of apoptosis in atherosclerosis and restenosis by terminal dutp nick-end labe... 19022819 - The pi3k/akt/mtor pathway in innate immune cells: emerging therapeutic applications. 19860669 - Cosignaling molecules around light-hvem-btla: from immune activation to therapeutic tar... 18927069 - Lipopolysaccharide-induced immune responses in relation to the tlr4(asp299gly) gene pol... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of experimental therapeutics & oncology Volume: 2 ISSN: 1359-4117 ISO Abbreviation: J. Exp. Ther. Oncol. Publication Date: 2002 Sep-Oct |
Date Detail:
|
Created Date: 2002-11-05 Completed Date: 2003-03-20 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 9604933 Medline TA: J Exp Ther Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 253-63 Citation Subset: IM |
Affiliation:
|
Drug Discovery and Development Program, Josephine Ford Cancer Center, Henry Ford Health System, Detroit, MI, USA. bsubram1@hfhs.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
pharmacology* Cell Cycle / drug effects DNA Damage DNA Topoisomerases, Type I / antagonists & inhibitors DNA, Neoplasm / biosynthesis Humans Mitotic Index Quinoxalines / pharmacokinetics, pharmacology* Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/DNA, Neoplasm; 0/Quinoxalines; 0/XK 469; EC 5.99.1.2/DNA Topoisomerases, Type I |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Src protein kinase pp60c-src influences adhesion stabilization of HT-29 colon carcinoma cells to ext...
Next Document: Severe folate restriction results in depletion of and alteration in the composition of the intracell...